Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

53.20
-1.3200-2.42%
Volume:285.09K
Turnover:15.14M
Market Cap:3.27B
PE:12.58
High:54.54
Open:54.45
Low:52.43
Close:54.52
Loading ...

Company Profile

Company Name:
Protagonist Therapeutics
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
126
Office Location:
7707 Gateway Boulevard,Suite 140,Newark,California,United States
Zip Code:
94560
Fax:
- -
Introduction:
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Directors

Name
Position
Dinesh V. Patel
Director, President and Chief Executive Officer
Bryan Giraudo
Indeendent Director
Chaitan Khosla
Indeendent Director
Harold E. Selick
Indeendent Director
Lewis T. Williams
Indeendent Director
Sarah Noonberg
Indeendent Director
William D. Waddill
Indeendent Director

Shareholders

Name
Position
Dinesh V. Patel
Director, President and Chief Executive Officer
Donald A. Kalkofen
Chief Financial Officer
David Y. Liu
Chief Scientific Officer and Head of Research and Development
Samuel Saks
Chief Medical Officer
Suneel Gupta
Chief Development Officer